Shilpa Medicare Ltd
SHILPAMEDShilpa Medicare Ltd
SHILPAMED![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/high_risk.png)
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
203.19 | 3.65 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Shilpa Medicare Limited is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) and intermediates, and wind power generation.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 724.00 | 798.83 | 810.50 | 786.96 | 924.85 | 992.11 | 1,168.76 | 1,067.51 | 1,165.90 | 1,165.92 | ||||||||||
Raw Materials | 374.23 | 418.27 | 313.83 | 256.81 | 293.78 | 329.56 | 390.24 | 404.42 | 911.88 | 911.88 | ||||||||||
Power & Fuel Cost | 24.44 | 26.30 | 28.86 | 33.57 | 38.76 | 40.25 | 52.43 | 56.79 | ||||||||||||
Employee Cost | 91.45 | 127.87 | 149.35 | 176.40 | 196.59 | 235.31 | 264.49 | 287.33 | ||||||||||||
Selling & Administrative Expenses | 49.33 | 48.39 | 59.02 | 54.50 | 115.69 | 104.32 | 158.09 | 116.52 | ||||||||||||
Operating & Other expenses | 26.96 | -2.26 | 82.79 | 84.26 | 43.65 | 11.77 | 80.28 | 86.58 | ||||||||||||
EBITDA | 157.59 | 180.26 | 176.65 | 181.42 | 236.38 | 270.90 | 223.23 | 115.87 | 254.02 | 254.04 | ||||||||||
Depreciation/Amortization | 28.63 | 30.64 | 37.22 | 42.06 | 43.78 | 53.98 | 79.80 | 95.50 | 107.87 | 107.88 | ||||||||||
PBIT | 128.96 | 149.62 | 139.43 | 139.36 | 192.60 | 216.92 | 143.43 | 20.37 | 146.15 | 146.16 | ||||||||||
Interest & Other Items | 6.86 | 3.13 | 2.66 | 3.68 | 4.56 | 21.87 | 41.17 | 58.65 | 91.81 | 91.81 | ||||||||||
PBT | 122.10 | 146.49 | 136.77 | 135.68 | 188.04 | 195.05 | 102.26 | -38.28 | 54.34 | 54.35 | ||||||||||
Taxes & Other Items | 18.32 | 38.92 | 31.52 | 23.42 | 31.91 | 47.27 | 41.60 | -5.80 | 22.47 | 22.47 | ||||||||||
Net Income | 103.78 | 107.57 | 105.25 | 112.26 | 156.13 | 147.78 | 60.66 | -32.48 | 31.87 | 31.88 | ||||||||||
EPS | 13.46 | 13.68 | 13.02 | 13.77 | 19.15 | 18.13 | 7.21 | -3.74 | 3.67 | 3.67 | ||||||||||
DPS | 0.60 | 0.60 | 0.70 | 1.00 | 1.10 | 1.10 | 1.10 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.04 | 0.04 | 0.05 | 0.07 | 0.06 | 0.06 | 0.15 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Shilpa Medicare Ltd | 203.25 | 3.65 | — |
Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare SHILPAMED with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 5.62%
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 2.65%
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 3.39%
Shareholding Pattern
Dec 2023
Mar 2024
Apr 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 3.44%
Top 5 Mutual Funds holding Shilpa Medicare Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.0790% | Percentage of the fund’s portfolio invested in the stock 1.78% | Change in the portfolio weight of the stock over the last 3 months 0.26% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/51 (-1) |
ICICI Prudential ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9083% | Percentage of the fund’s portfolio invested in the stock 0.42% | Change in the portfolio weight of the stock over the last 3 months 0.42% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 47/81 (+26) |
Bandhan Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8563% | Percentage of the fund’s portfolio invested in the stock 0.94% | Change in the portfolio weight of the stock over the last 3 months 0.94% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 144/180 (+11) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2022
Dividend/Share
₹1.10
Ex DateEx Date
Sep 19, 2022
Cash Dividend
Ex DateEx DateSep 20, 2021
Dividend/Share
₹1.10
Ex DateEx Date
Sep 20, 2021
Cash Dividend
Ex DateEx DateMar 16, 2020
Dividend/Share
₹1.10
Ex DateEx Date
Mar 16, 2020
Cash Dividend
Ex DateEx DateSep 12, 2019
Dividend/Share
₹1.00
Ex DateEx Date
Sep 12, 2019
Cash Dividend
Ex DateEx DateMar 1, 2018
Dividend/Share
₹0.70
Ex DateEx Date
Mar 1, 2018
Shilpa Biologicals (SBPL), a wholly owned subsidiary of Shilpa Medicare has received registration approval for Adalimumab from Morocco, MoH. This is the first Biosimilar approval from any international market for high concentration Adalimumab developed by SBPL. Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL). Adalimumab contains Adalimumab as an active ingredient. Adalimumab is a fully human monoclonal IgG1 antibody produced recombinantly by Chinese Hamster Ovary (CHO)cells. Adalimumab consists of 1330 amino acid containing glycoprotein which has two copies of heavy- and two copies of light-chains in heterodimeric form with a molecular weight of 148 kDa (approx.). Adalimumab binds specifically to Tumor Necrosis Factor-alpha (TNF-') and blocks its interaction with the p55 and p75 cell surface TNF receptor. Adalimumab is indicated for Rheumatoid Arthritis (RA) in adults. The Adalimumab 40 mg/ 0.4 mL Solution for Injection is highly similar to the innovator (Humira) with respect to Quality, Safety and Efficacy. SBPL has aggressively submitted its Adalimumab dossier in more than 15 emerging markets countries and is in the process of submitting the dossier to other countries as well. Powered by Capital Market - Live
Shilpa Medicare's 100% subsidiary, Shilpa Pharma Lifesciences' Active Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state has undergone a GMP inspection by COFEPRIS-Mexico from November 6-10, 2023. Following a successful inspection, the Unit has been issued GMP Certification from COFEPRIS-MexicoPowered by Capital Market - Live
Shilpa Medicare subsidiary’s Karnataka facility clears GMP inspection
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Stock Alert: JSW Steel, Delta Corp, Rail Vikas Nigam, Adani Power, Shilpa Medicare
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
![](https://i4.ytimg.com/vi/wk_RH4Dw19M/hqdefault.jpg)
Shilpa Medicare sizzles after Unicycive gets positive results in clinical trials of OLC
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Raymond Ltd leads gainers in ‘A’ group
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
This pharma stock has surged 16% on Friday; zoomed over 100% so far in CY24
![](https://pocket-image-cache.com/direct?url=http://bsmedia.business-standard.com/_media/bs/img/article/2024-05/30/thumb/featurecrop/400X400/1717054109-7223.jpg)
Shilpa Medicare Shares Jump 5% On Oral Drug Delivery System Nod
![](https://pocket-image-cache.com/direct?url=http://media.assettype.com/bloombergquint%2F2023-12%2F964bfb36-7ad1-45e3-ba71-42cfd4eff00b%2Froberto_sorin_RS0_h_pyByk_unsplash.jpg?w=1200&auto=format%2Ccompress&ogImage=true)
Stocks to watch on August 1, 2023
![](https://pocket-image-cache.com/direct?url=http://bl-i.thgim.com/public/news/xektxc/article67131205.ece/alternates/LANDSCAPE_1200/stock%20market%20021402153.jpg)
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 8.18%, vs industry avg of 8.96%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.35% to 0.32%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -22.26%, vs industry avg of 15.15%